Search results for "Adolescent"

showing 10 items of 6718 documents

Mortality risk among 5‐year survivors of childhood cancer in Germany—Results from the CVSS study (Cardiac and Vascular late Sequelae in long‐term Sur…

2021

The growing population of long-term childhood cancer survivors is at increased risk for severe, therapy-related late effects and premature mortality. The cardiac and vascular late sequelae in long-term survivors of childhood cancer (CVSS) study is a cohort of patients from Germany diagnosed with a neoplasia prior to 15 years of age in the time period 1980 to 1990. Late mortality was evaluated in a total of 4505 individuals who survived 5 years or more after the initial diagnosis (5-year survivors). Survivors with a second primary tumor were excluded. Standardized mortality ratios (SMRs) were calculated. By December 2014, 400 patients had died. Available cause of death information from 188 i…

AdultMaleCancer ResearchPediatricsmedicine.medical_specialtyTime FactorsAdolescentPopulationChildhood cancerYoung AdultCancer SurvivorsCause of DeathGermanyNeoplasmsmedicineHumansMortalityChildeducationRetrospective StudiesCause of deatheducation.field_of_studybusiness.industryInfant NewbornInfantCancerPrognosismedicine.diseaseConfidence intervalSurvival RateOncologyCardiovascular DiseasesChild PreschoolCVSSCohortDisease ProgressionFemalebusinessFollow-Up StudiesCohort studyInternational Journal of Cancer
researchProduct

Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and …

2015

AbstractHaematological malignancies (HM) represent over 6% of the total cancer incidence in Europe and affect all ages, ranging between 45% of all cancers in children and 7% in the elderly. Thirty per cent of childhood cancer deaths are due to HM, 8% in the elderly. Their registration presents specific challenges, mainly because HM may transform or progress in the course of the disease into other types of HM. In the context of cancer registration decisions have to be made about classifying subsequent notifications on the same patient as the same tumour (progression), a transformation or a new tumour registration. Allocation of incidence date and method of diagnosis must also be standardised…

AdultMaleCancer ResearchPediatricsmedicine.medical_specialtyTransformationsAdolescentContext (language use)Cancer registrationDiseaseCancer registrationMedical RecordsYoung AdultENCREpidemiologymedicineHumansRegistriesMortalityMedical diagnosisEurocourseChildEarly Detection of CancerAgedAged 80 and overbusiness.industryIncidence (epidemiology)Infant NewbornInfantCancerMiddle Agedmedicine.disease3. Good healthSurgeryCell Transformation NeoplasticOncologyCancer incidenceChild PreschoolHematologic NeoplasmsEpidemiological MonitoringDisease ProgressionFemalebusinessHaematologyEuropean Journal of Cancer
researchProduct

Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer:The PanCareS…

2022

Late mortality of European five-year survivors of childhood or adolescent cancer has dropped over the last 60 years, but excess mortality persists. There is little information concerning secular trends in cause-specific mortality among older European survivors. PanCareSurFup pooled data from 12 cancer registries and clinics in 11 European countries from 77 423 five-year survivors of cancer diagnosed before age 21 between 1940 to 2008 followed for an average age of 21 years and a total of 1.27 million person-years to determine their risk of death using cumulative mortality, standardized mortality ratios (SMR), absolute excess risks (AER), and multivariable proportional hazards regression ana…

AdultMaleCancer ResearchSecond NeoplasmsAdolescentAdolescent cancercauses of deathEuropean03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsCause of DeathMedicineHumans030212 general & internal medicineCause specificChild610 Medicine & healthAgedExcess mortalitybusiness.industrycardiovascularsecond malignant neoplasmsHazard ratioCancersurvivors of childhood cancerMiddle Agedmedicine.diseaseConfidence interval3. Good healthOncologyEuropean; cardiovascular; causes of death; late mortality; second malignant neoplasms; survivors of childhood cancer030220 oncology & carcinogenesisChild Preschoollate mortalityFemaleRisk of deathbusiness360 Social problems & social servicesDemography
researchProduct

Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy

2020

In Oceania, North America and north-western Europe, after decades of increase, cutaneous malignant melanoma (CMM) rates began to stabilise or decline before 2000. Anecdotal evidence suggests that the reversal of the incidence trend is extending to southern Europe. To obtain a formal confirmation, this nationwide study from Italy investigated the incidence trends by birth cohort. Twenty-one local cancer registries covering a population of 15 814 455 provided incidence data for primary CMM registered between 1994 and 2013. Trends in age-standardised rates were analysed using joinpoint regression models and age-period-cohort models. Age-standardised incidence showed a consistent increase throu…

AdultMaleCancer ResearchSkin NeoplasmsAdolescentAge-period-cohort modelling birth cohort cutaneous malignant melanoma incidence time trendPopulationSocio-culturaleRate ratioSettore MED/42 - Igiene Generale E ApplicataRisk AssessmentYoung Adult03 medical and health sciences0302 clinical medicineage-period-cohort modellingHumansMedicineRegistrieseducationMelanomaAgedAged 80 and overeducation.field_of_studyGeographybusiness.industryIncidence (epidemiology)Melanomabirth cohortMiddle Agedmedicine.diseaseConfidence intervalAnnual Percent Changetime trendItalyOncology030220 oncology & carcinogenesisCohortincidenceFemalebusinessBirth cohortcutaneous malignant melanomaDemography
researchProduct

Time trends and short term projections of cancer prevalence in France

2018

IF 2.888 (2017); International audience; BackgroundThis study analyzes time trends in cancer prevalence in France and provides short-term projections up to the year 2017. The 15-year prevalence for 24 cancers was estimated from the French cancer registries network (FRANCIM) incidence and survival data.MethodWe estimated prevalence using the P = I × S relationship, with flexible modeling of incidence and survival. Based on observations of the incidence and survival up to 2010, different scenarios for evolution up to 2017 were studied, combining stable and dynamic incidence and survival. The determinants of variations in prevalence (incidence, survival and demography) were quantified.ResultsA…

AdultMaleCancer ResearchTime FactorsAdolescentEpidemiologyPopulation[SDV.CAN]Life Sciences [q-bio]/Cancer030501 epidemiologyProjection scenariosYoung Adult03 medical and health sciences0302 clinical medicineSurvival dataNeoplasmsPrevalencemedicineHumansRegistrieseducationCancer prevalenceAgedAged 80 and overeducation.field_of_studybusiness.industryTime trendsIncidenceIncidence (epidemiology)CancerTime trendsMiddle AgedPrognosismedicine.diseaseShort-term projections3. Good healthSurvival RateOncologyDemographic change030220 oncology & carcinogenesisFemaleFranceFlexible models0305 other medical sciencebusinessDemographyCancer Epidemiology
researchProduct

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: first results from a patient survey by the German Study Group for M…

2021

AdultMaleCancer Researchmedicine.medical_specialty2019-20 coronavirus outbreakAdolescentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEGermanYoung AdultGermanySurveys and QuestionnairesInternal medicineCorrespondencemedicineHumansAgedAged 80 and overMyeloproliferative DisordersSARS-CoV-2business.industryCOVID-19HematologyMiddle AgedPrognosisTelemedicinelanguage.human_languageOncologylanguageFemalePatient surveybusinessFollow-Up StudiesLeukemia Research
researchProduct

Risk factors for classical Kaposi's sarcoma.

2002

Background: Classical Kaposi's sarcoma (KS) is a malignancy of lymphatic endothelial skin cells. Although all forms of KS are associated with the KS-associated herpesvirus (KSHV), classical KS occurs in a small fraction of KSHV-infected people. We sought to identify risk factors for classical KS in KSHV-infected individuals. Methods: Lifestyle and medical history data from case patients with biopsyproven non-AIDS (non-acquired immunodeficiency syndrome) KS in Italy were compared by logistic regression analysis with data from population-based KSHV-seropositive control subjects of comparable age and sex. After KSHV immunofluorescence testing, randomly selected patients on the rosters of local…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentAdministration TopicalPopulationAnti-Inflammatory AgentsAntibodies ViralRisk FactorsInternal medicineEpidemiologymedicineConfidence IntervalsOdds RatioHumansMedical historyRisk factoreducationMedical History TakingKaposi's sarcomaGlucocorticoidsLife StyleSarcoma KaposiAsthmaAgedAged 80 and overeducation.field_of_studybusiness.industrySmokingHygieneOdds ratioHerpesviridae InfectionsMiddle Agedmedicine.diseaseConfidence intervalAsthmaOncologyItalyCase-Control StudiesImmunologyHerpesvirus 8 HumanMultivariate AnalysisFemalebusinessJournal of the National Cancer Institute
researchProduct

Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study.

2016

Rectal cancer is a common and serious disease. The aim of the SUDCAN collaborative study was to compare the net survival from rectal cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study-period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses …

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentDatabases FactualEpidemiologyColorectal cancer03 medical and health sciencesYoung Adult0302 clinical medicineBelgiumEpidemiologymedicineHumansRegistriesYoung adultSurvival rateNet SurvivalMass screeningAgedExcess mortalityAged 80 and overPortugalbusiness.industryRectal NeoplasmsPublic Health Environmental and Occupational HealthMiddle Agedmedicine.disease3. Good healthPopulation based studyEuropeSurvival RateOncologyItalySpain030220 oncology & carcinogenesisPopulation Surveillance030211 gastroenterology & hepatologyFemaleFrancebusinessSwitzerlandDemographyEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century.

2012

This study provides up-to-date and detailed cancer survival estimates of German patients with non-Hodgkin lymphoma (NHL, International Statistical Classification of Diseases 10th Revision [ICD-10] codes C82-C85) based on data from 11 cancer registries. Period analysis was used to calculate 5-year relative survival in 2002-2006, overall and by gender, age and histology. Comparison was made with patients with NHL in the United States (US) Surveillance, Epidemiology and End Results database in the same time period. Overall 5-year relative survival for patients with NHL in Germany in 2002-2006 was 62.8% and in the US was 65.1%. Survival decreased with age from 81.7% at age 15-49 to 46.5% at age…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentFollicular lymphomaHistory 21st CenturyYoung AdultOlder patientshemic and lymphatic diseasesInternal medicineGermanyEpidemiologymedicineHumansRegistriesAgedAged 80 and overRelative survivalbusiness.industryLymphoma Non-HodgkinCancerHematologyHistory 20th CenturyMiddle Agedmedicine.diseaseUnited StatesLymphomaOncologyImmunologyPeriod AnalysisHodgkin lymphomaFemalebusinessSEER ProgramLeukemialymphoma
researchProduct

The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry.

2014

Our specialized population-based registry has allowed us to explore changes in incidence and survival by subtype over the last 30 years. Between 1980 and 2009, 4790 cases of lymphoid malignancies were registered using the International Classification of Diseases for Oncology. The incidence rate of lymphoid malignancies was 20.5 per 100,000 inhabitants per year, and ranged from 0.1 to 4 according to subtype. Five-year net survival was 65%, and ranged from 41% to 93% according to subtype. We observed an increase in 5-year net survival between the periods 1980-1989 and 2000-2009 (58% vs. 70%). This was observed in most but not all subtypes. Our long-standing population-based registry allowed u…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentLymphomaPopulationYoung AdultSurvival probabilityInternal medicinemedicineHumansRegistrieseducationChildNet SurvivalAgedAged 80 and overeducation.field_of_studyLeukemiabusiness.industryIncidence (epidemiology)IncidenceHematologyMiddle AgedSurvival AnalysisCancer registryOncologyLymphoid malignancyChild PreschoolHematologic NeoplasmsPopulation SurveillanceImmunologyFemaleFrancebusinessPopulation-Based RegistryInternational Classification of Diseases for OncologyFollow-Up StudiesLeukemialymphoma
researchProduct